Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: A double-blind and randomized trial

Child Psychiatry and Human Development

Volumn 41, Issue 6, 2010, Pages 641-648

  Davari Ashtiani, Rozita ^a,b   Shahrbabaki, Mahin Eslami ^a   Razjouyan, Katayoon ^a   Amini, Homayoun ^c,d   Mazhabdar, Homa ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADHD; Buspirone; Methylphenidate

Indexed keywords

BUSPIRONE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; SEROTONIN AGONIST;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUSPIRONE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; METHYLPHENIDATE; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 79952276590     PISSN: 0009398X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10578-010-0193-2     Document Type: Article

References (29)

1. Rowland AS, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 8(3):162-170
2. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV et al (2005) Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry 57:1442-1451
3. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE et al (1995) Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56:993-998
4. Raskin LA, Shaywitz BA, Anderson GM, Cohen DJ, Teicher MH, Linakis J (1983) Differential effects of selective dopamine, norepinephrine or catecholamine depletion on activity and learning in the developing rat. Pharmacol Biochem Behav 19:743-749
5. Shaywitz BA, Teicher MH, Cohen DJ, Anderson GM, Young JG, Levitt P (1984) Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharmacology (Berl) 82:73-77
6. Shekim WO, Dekirmenjian H, Chapel JL (1979) Urinary MHPG excretion in minimal brain dysfunction and its modification by d-amphetamine. Am J Psychiatry 136:667-671
7. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54:857-864
8. Safer DJ (1997) Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990 s. J Child Adolesc Psychopharmacol 7:267-274
9. Wilens TE, Biederman J (1992) The stimulants. Psychiatr Clin North Am 15:191-222
10. Arnold LE (2000) Methyiphenidate vs. amphetamine: comparative review. J Atten Disord 3:200-211
11. Findling RL, Schwartz MA, Flannery DJ, Manos MJ (1996) Venlafaxine in adults with attention-deficit/ hyperactivity disorder: an open clinical trial. J Clin Psychiatry 57:184-189
12. Klein RG, Landa B, Mattes JA, Klein DF (1988) Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45:1127-1130
13. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM (1993) Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065-1072
14. Kehoe WA (2001) Treatment of attention deficit hyperactivity disorder in children. Ann Pharmacother 35:1130-1134
15. Prince JB, Wilens TE, Biederman J, Spencer TJ, Millstein R, Polisner DA et al (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193-204
16. Temple DL Jr, Yevich JP, New JS (1982) Buspirone: chemical profile of a new class of anxioselective agents. J Clin Psychiatry 43:4-10
17. Taylor D, Hyslop D (1991) Chronic administration of buspirone down-regulates 5-HT2 receptor binding sites. Drug Dev Res 24:93-105
18. Tunnicliff G, Brokaw JJ, Hausz JA, Matheson GK, White GW (1992) Influence of repeated treatment with buspirone on central 5-hydroxytryptamine and dopamine synthesis. Neuropharmacology 31: 991-995
19. Castillo C, Ibarra M, Marquez AJ, Villalobos-Molina R, Hong E (1993) Vascular effects of ipsapirone are related with subtypes of alpha 1-adrenergic receptors. Arch Med Res 24:161-168
20. Castillo C, Ibarra M, Marquez JA, Villalobos-Molina R, Hong E (1993) Pharmacological evidence for interactions between 5-HT1A receptor agonists and subtypes of alpha 1-adrenoceptors on rabbit aorta. Eur J Pharmacol 241:141-148
21. Sanghera MK, McMillen BA, German DC (1982) Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity. Eur J Pharmacol 86:107-110
22. Malhotra S, Santosh PJ (1998) An open clinical trial of buspirone in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 37:364-371
23. Niederhofer H (2003) An open trial of buspirone in the treatment of attention-deficit disorder. Hum Psychopharmacol 18:489-492
24. Neppe V, Young Z (2003) Buspirone as a new treatment for attention deficit disorder and aggression in children and adolescents. Austral J Psychopharmacol 10:47-56
25. Gross MD (1995) Buspirone in ADHD with ODD. J Am Acad Child Adoles Psychiatry 34:1260
26. DuPaul G (1991) Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. J Clin Child Psychol 20:245-253
27. Park E, Cho M, Ki C (2009) Correct use of repeated-measures analysis of variance. Korean J Lab Med 29:1-9
28. Neppe V (1990) Innovative psychopharmacotherapy. Raven Press, New York
29. Neppe V (1999) Cry the beloved mind: a voyage of hope. Brainquest Press DBA Brainvoyage.com, Seattle